Genomics In-Depth Focus 2019
In this In-Depth Focus are articles on how genomics could revolutionise clinical treatment and an insight into the promise and pitfalls of using CRISPR.
List view / Grid view
In this In-Depth Focus are articles on how genomics could revolutionise clinical treatment and an insight into the promise and pitfalls of using CRISPR.
This issue includes an investigation into utilising recombinant antibodies for research, a highlight on protein design using computational methods and an examination of the advances in genomic medicine. Also in the issue are articles on next generation sequencing and upstream bioprocessing.
This article highlights five of the latest findings that could be used in the development or design of new therapies to treat Parkinson’s disease.
A report from scientists at the Moscow Institute of Physics and Technology highlights the advantages and disadvantages of serial femtosecond X-ray crystallography. This article investigates the review, focusing on its role in drug development.
Dr Shona Lang investigates the advantages and disadvantages of using organoids within R&D, highlighting the most important questions to ask before using these models.
AI has applications in many areas of research, including genomics. Slavé Petrovski of AstraZeneca reveals how AI is used in the study of the human genome and how it may evolve in the future.
Claus Bendtsen at AstraZeneca reveals how AI can be used to improve our understanding of disease, to help identify the causes of conditions and aid in drug discovery.
Designing new drug molecules is crucial to R&D. Dr Sam Genway suggests that one way to improve and speed up this process is using AI inspired by language translation.
Imaging methods are used by scientists to identify therapeutic targets and improve drug efficacy. This article lists five of the latest developments for imaging techniques.
A review has been published by experts in neurodegeneration research, detailing six ways to improve dementia research. This article investigates one of these suggestions, focusing on how we can improve drug target identification.
The use of models is a key feature of preclinical studies and in recent months there have been several new advancements in this area. This article investigates five of the latest developments.
From the world’s flagship neutron science facility, Institut Laue-Langevin (ILL), Matthew Blakeley shares insights into how they are harnessing the power of neutrons to aid their search for new cancer treatments.
Charlotte Walker-Osborn, a Partner and Head of Technology Sector (International) at global law-firm Eversheds Sutherland and a legal expert in technology law, explains some of the challenges and potential future of artificial intelligence (AI) in the field of drug discovery.
The potential of three-dimensional cell culture models is now well-recognised by scientists; however, there are still some challenges. Margaritha Mysior and Jeremy Simpson address some of the common challenges of working with spheroids and organoid models – including how they are developed and how to obtain high-resolution, high-content images and…
This article outlines the exciting developments that are taking place with immunotherapies and demonstrates how stem-cell technologies are proliferating the paradigm shift in how we tackle cancer treatment.